Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV
暂无分享,去创建一个
[1] H. Stellbrink,et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Vos,et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. , 2019, New England Journal of Medicine.
[3] M. Peeters,et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. , 2019, The New England journal of medicine.
[4] M. Blüher. Obesity: global epidemiology and pathogenesis , 2019, Nature Reviews Endocrinology.
[5] A. Mocroft,et al. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial , 2019, PloS one.
[6] L. Waters,et al. Are new antiretroviral treatments increasing the risks of clinical obesity? , 2019, Journal of virus eradication.
[7] D. Marks,et al. Melanocortin-3 receptors expressed on agouti-related peptide neurons inhibit feeding behavior in female mice. , 2018, Obesity.
[8] N. Ford,et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? , 2018, AIDS.
[9] Mark D. Ericson,et al. Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice. , 2018, ACS chemical neuroscience.
[10] H. Crystal,et al. Ghrelin, Amylin, Gastric Inhibitory Peptide and Cognition in Middle-Aged HIV-Infected and Uninfected Women: The Women’s Interagency HIV Study , 2017, Alzheimer's & Dementia.
[11] F. Villarroya,et al. Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. , 2016, Antiviral research.
[12] A. Mocroft,et al. Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study , 2016, HIV medicine.
[13] M. Hughes,et al. A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings , 2015, Open forum infectious diseases.
[14] F. Villarroya,et al. A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz , 2014, Journal of acquired immune deficiency syndromes.
[15] V. Taylor,et al. Changes in Body Weight and Psychotropic Drugs: A Systematic Synthesis of the Literature , 2012, PloS one.
[16] F. Villarroya,et al. HIV Type-1 Transgene Expression in Mice Alters Adipose Tissue and Adipokine Levels: Towards a Rodent Model of HIV Type-1 Lipodystrophy , 2010, Antiviral therapy.
[17] Subhajyoti De,et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity , 2008, Nature Genetics.
[18] R. Cone,et al. Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. , 2007, Endocrinology.
[19] U. Hengge,et al. Increased neuropeptide Y-like immunoreactivity in cerebrospinal fluid and plasma of human immunodeficiency virus-infected patients: relationship to HIV encephalopathy , 1996, Journal of the Neurological Sciences.